Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease.
Publication/Presentation Date
11-1-2022
Abstract
OBJECTIVE: Intravenous administration of gadolinium-based contrast agents (GBCA) in patients with impaired renal function has been of concern to primary care physicians due to the potential worsening of renal dysfunction and nephrogenic systemic fibrosis (NSF). Our objective was to compare the potential change in estimated glomerular filtration rate (eGFR) in patients with known severe renal dysfunction (eGFR/min), following Gadoterate meglumine (GM) administration with patients who do not receive contrast.
METHODS: An IRB-approved retrospective analysis of all patients who underwent MRI examination at our institution, for any indication, between January 2016 and September 2020.
INCLUSION CRITERIA: pre-MRI eGFR/min within 24 h of MRI, follow-up eGFR between 48 and 96 h post-MRI, and absence of peritoneal or hemodialysis. The individuals who received GM (492 scans) were identified as cases, and those who did not receive contrast (1101 scans) were identified as controls for our study. Delta-eGFR response was calculated and covariate-adjusted, and propensity score analysis was performed.
RESULTS: No significant eGFR decrease was observed in patients who received GM compared to those who did not receive GM in our study. Also, no relationship between comorbidity, severity and contrast selection was observed.
CONCLUSION: The use of Gadolinium contrast in MRI is often of critical importance for determining accurate anatomic relationships, differentiation of benign from malignant lesions, or determination of resolving vs. worsening disease. Though the risk of contrast administration can never be entirely ignored, especially in patients with low eGFR, our study indicates that safe administration of GM can be performed even in patients with severe kidney disease.
Volume
91
First Page
126
Last Page
131
ISSN
1873-4499
Published In/Presented At
Jawahar, A., El-Bulbul, J., Adams, W., Joyce, C., Yacoub, J., & Goldberg, A. (2022). Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease. Clinical imaging, 91, 126–131. https://doi.org/10.1016/j.clinimag.2022.08.021
Disciplines
Diagnosis | Medicine and Health Sciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Radiology
PubMedID
36075185
Department(s)
Department of Radiology and Diagnostic Medical Imaging
Document Type
Article